HOTH - Hoth signs agreement to evaluate platform on ulcerative colitis Crohn's

Microcap Hoth Therapeutics (HOTH) has signed an agreement with contract research organization REPROCELL Ltd. to evaluate the HT-003 platform on tissue from ulcerative colitis and Crohn's patients.Hoth says that HT-003's active pharmaceutical ingredient is an inhibitor of retinoic acid metabolism (known as a RAMBA), adding that recent literature suggests that abnormal retinoic acid regulation may contribute to the underlying inflammatory mechanism that causes inflammatory bowel disease symptoms and restoring this regulation can help.HT-003 just entered a new phase of preclinical studies this quarter.Hoth is developing HT-003 in collaboration with Weill Cornell Medicine.Hoth shares are up 4.7% to $1.99 in afternoon trading.

For further details see:

Hoth signs agreement to evaluate platform on ulcerative colitis, Crohn's